Trial · NCT02090283
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo to SD-101-6.0 | Any TEAE | 13 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | SD-101-3.0 to SD-101-6.0 | Any TEAE | 14 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | SD-101-6.0 to SD-101-6.0 | Any TEAE | 5 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo to SD-101-6.0 | Any TEAE Related to Study Drug | 1 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | SD-101-3.0 to SD-101-6.0 | Any TEAE Related to Study Drug | 1 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | SD-101-6.0 to SD-101-6.0 | Any TEAE Related to Study Drug | 0 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo to SD-101-6.0 | Any Fatal TEAE | 0 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | SD-101-3.0 to SD-101-6.0 | Any Fatal TEAE | 0 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | SD-101-6.0 to SD-101-6.0 | Any Fatal TEAE | 0 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo to SD-101-6.0 | Serious TEAE | 4 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | SD-101-3.0 to SD-101-6.0 | Serious TEAE | 2 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | SD-101-6.0 to SD-101-6.0 | Serious TEAE | 0 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo to SD-101-6.0 | Any TEAE Leading to Discontinuation | 1 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | SD-101-3.0 to SD-101-6.0 | Any TEAE Leading to Discontinuation | 1 | Participants | |
| Number Of Participants With Treatment-Emergent Adverse Events (TEAEs) | SD-101-6.0 to SD-101-6.0 | Any TEAE Leading to Discontinuation | 0 | Participants | |
| Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 24 | Placebo to SD-101-6.0 | 1.99 | Standard Deviation 6.728 | percentage of BSAI | |
| Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 24 | SD-101-3.0 to SD-101-6.0 | -3.73 | Standard Deviation 6.152 | percentage of BSAI | |
| Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 24 | SD-101-6.0 to SD-101-6.0 | -9.50 | Standard Deviation 21.248 | percentage of BSAI |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02090283/results